Coronavirus — Vaccines and Politics

  • Pfizer expects to cut the time of the Covid-19 vaccine in half.
  • The pre-orders of the Covid-19 have not been fully filled by Pfizer and Moderna.
  • The Sputnik-V vaccine is one of the best vaccines on the market.

The Coronavirus pandemic continues to be a major factor around the world. Currently, there are over 107 million infected and over 2.3 million deaths around the globe. Many countries are experiencing shortages of the COVID-19 vaccines. The COVID-19 restrictions continue to hurt the global economies.

Moderna’s Covid-19 vaccine is the second to receive an emergency use authorization from the FDA.

Last month, the Canadian province of Ontario experienced one of its largest job losses. Even though there is a discussion regarding the easement of the restrictions in Canada, there are still real fears from the health officials of a possible third wave this spring.

Furthermore, the positive reports about the effectiveness of the Pfizer-BioNTech and Moderna vaccines at the level of 95-98% inspired the public. The AstraZeneca vaccine’s statements, of about 65% effectiveness in general, and about 100% effectiveness against severe cases did not discourage the general public.

Nevertheless, the Western vaccines ran into a few serous issues. One of the issues includes the inconsistent quality of the test samples in mass production. In addition, the pre-orders of the vaccine are still not filled in full. Pfizer is hoping to cut production of its COVID-19 vaccine in half. Possible side effects of each vaccine also remain a concern, and are still under investigation.

Russia’s Sputnik V vaccine became the subject of political bargaining rather than a real business process. Last week, one of the prestigious publications, The Lancet, published the results and success of the Sputnik V vaccine, making it one of the best vaccines on the market.

Some nations offered to purchase the Sputnik V vaccine, only the vaccine would be manufactured at local facilities. Russia was not opposed to the licensing deals. Thus far, Brazil and India, and a number of Latin American nations, will be producing the vaccine at their facilities.

Gam-COVID-Vac, trade-named Sputnik V, is a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology, and registered on 11 August 2020 by the Russian Ministry of Health.

However, there is an issue of capabilities to produce large volumes of the vaccine outside of Russia. Therefore, there still will be the need to purchase the Russian-made Sputnik V vaccine.

In the case of Western Europe, Alexei Navalny’s situation may preclude those countries from purchasing the Russian vaccine, even though there are shortages of their own COVID-19 vaccines at dangerous levels. Additionally, Germany could easily produce Sputnik V due to its pharmacological infrastructure and the manufacturing facilities.

Thus far, Germany has not commented in regards to the Russian vaccine. Hungary and Slovakia seem to be eager to get the Sputnik V vaccine, but they are trying to use political bargaining.

It is expected that Sputnik V will receive European certification fairly soon. The question remains, would these countries put the needs and heath of their citizens ahead of political ideology and Mr. Navalny?

Overall, it is clear, the Coronavirus pandemic needs to be contained and the global economies need to to enter their own recovery processes.

Christina Kitova

I spent most of my professional life in finance, insurance risk management litigation.

Leave a Reply